Key insights
- Mizuho raised its price target on Teleflex (TFX) to $140 after a Q1 earnings beat. The company's new CEO and restructuring efforts are viewed positively, with potential for further upside. However, execution risks and timing concerns keep the rating at Neutral. RBC Capital also upgraded the stock. Overall, the news suggests a slightly positive outlook for TFX, but broader market implications are limited.
Investing.com - Mizuho raised its price target on Teleflex Inc. shares (NYSE:TFX) to $140 from $135 while maintaining a Neutral rating on the stock. The shares currently trade at $131.68, just 6% below their 52-week high of $139.67, following a strong 21% surge over the past six months.
The medical device company beat first-quarter expectations with sales 3% above estimates and adjusted earnings per share of $0.20, or 17%, above projections. Sales growth of 5% aligned with the company’s organic sales growth outlook for its RemainCo business following divestitures.
New CEO Jason Weidman joined Teleflex with decades of experience from Medtronic, bringing a track record of driving growth in similar businesses. The company operates as a streamlined organization following its restructuring.
Mizuho sees potential for the stock to return to $175 or higher in standalone value for the RemainCo business, justified by a multiple of approximately 15 to 18 times on adjusted earnings per share of around $10 or more. This aligns with InvestingPro analysis, which suggests the stock appears undervalued at current levels. The firm raised its price target to reflect progress in solidifying the business ahead of debt paydown, share repurchase, and cost reduction initiatives following asset sales.
The firm cited timing and execution risks as reasons for maintaining its Neutral rating. The company faces potential upside later in the year following disruptions from an accessory recall.
In other recent news, Teleflex Incorporated reported impressive first-quarter 2026 financial results, surpassing analysts’ expectations. The company achieved an adjusted earnings per share (EPS) of $1.39, exceeding the projected $1.21. Additionally, revenue reached $548.3 million, outperforming the anticipated $537.59 million. These figures highlight Teleflex’s strong financial performance in the early part of the year.
Furthermore, RBC Capital has upgraded Teleflex’s stock rating from Sector Perform to Outperform, raising the price target from $135 to $155. This upgrade was influenced by Teleflex’s ongoing business transformation initiatives and the recent appointment of Jason Weidman, formerly of Medtronic, as the incoming CEO. RBC analyst Shagun Singh emphasized Weidman’s proven leadership in medical technology growth as a positive factor for the company. These developments reflect a period of significant change and growth for Teleflex.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.